BioInteractions Relaunches Antithrombogenic Coating at COMPAMED
By Michael Barbella, Managing Editor | 11.16.23
Company targets new procedures including heart valves, haemodialysis, and brain implants.
BioInteractions Ltd. is re-releasing its most advanced antithrombogenic coating, Astute, this week at Compamed.
Billed as the world's only non-leaching active antithrombogenic coating, Astute is being targeted for heart valve replacements, haemodialysis systems, neurological implants, and oxygenators where the implant is required to stay in the body for extensive periods of time. Thanks to its clinical recognition for being safe to use on Class III blood contacting medical devices, BioInteractions is offering Astute as an answer to serious issues including increasing healthcare associated infections (HAIs) and medical device rejection.
Millions of people improve their health every year due to an implanted medical device. However, the body frequently rejects implanted devices, and there currently are no consistently effective strategies to prevent or suppress rejection. This makes the requirement for strategies to improve implants and reduce implant-caused thrombosis even more critical, not only to help resolve these issues but also increase patient safety.
BioInteractions has developed Astute to improve device surface hemocompatibility by mimicking the endothelial layer. The coating has obtained clinical recognition for its safe and successful use on Class III blood contacting medical devices for more than 30 years. The multi-action technology confronts clot formation on devices to provide biocompatibility and antithrombogenicity over long periods of time. Astute contains an active component that interrupts the blood cascade mechanism, preventing platelets from activating and hinders thrombus formation. This ensures the blood remains inactive and does not clot further along in the patient. The coating combines this with passive non-thrombogenic elements to prevent deposition and adhesion on the device surface, enhancing the overall antithrombogenic efficacy. Astute uses only non-leaching components, which reduces patient risk and helps the coating to continue performing without reduction in performance over time.
“We understand the significant risks of both device rejection and increasing HAIs to patient safety, which is why we have worked very hard to develop our non-leaching, antithrombogenic coating solution Astute®,” BioInteractions Commercial Director Arjun Luthra explained. “Thanks to advances in terms of Astute’s platelet adhesion (prevents 95% of platelet formation) and platelet activation (halts blood cascade mechanism by 92%), we have achieved results of more than 98% reduction in blood clot formation. What this all means is that we have a coating solution that when implemented on an indwelling device, turns it into a permanent implant that has improved performance, therefore enhancing life with an implant, whilst reducing the need for further surgeries and ultimately, improving patient safety.”
BioInteractions has more than 30 years experience in R&D, specializing in biocompatible material technologies for the global medical device industry. Based in purpose-built laboratories in the Thames Valley Science Park at the University of Reading (United Kingdom), the company develops advanced and specialized coatings for devices used in medical treatments and procedures ranging from Class I to Class III implants. The company has been a critical supplier to the medical device industry; its portfolio of multi-action materials confronts chronic challenges such as thrombus formation, infections, complications at the tissue-device interface, and various other biocompatible challenges faced by partners. BioInteractions has secured licensing contracts with major medical device manufacturers worldwide and, in 2002, won the Queen’s Award for Enterprise for a biocompatible coating that was the first to combine multiple elements for enhanced long-term antithrombogenic activity for all materials and shapes in just one coating.
BioInteractions is exhibiting at Compamed, Hall 8B, stand number N20. Compamed runs through Nov. 16 in Düsseldorf, Germany.
Billed as the world's only non-leaching active antithrombogenic coating, Astute is being targeted for heart valve replacements, haemodialysis systems, neurological implants, and oxygenators where the implant is required to stay in the body for extensive periods of time. Thanks to its clinical recognition for being safe to use on Class III blood contacting medical devices, BioInteractions is offering Astute as an answer to serious issues including increasing healthcare associated infections (HAIs) and medical device rejection.
Millions of people improve their health every year due to an implanted medical device. However, the body frequently rejects implanted devices, and there currently are no consistently effective strategies to prevent or suppress rejection. This makes the requirement for strategies to improve implants and reduce implant-caused thrombosis even more critical, not only to help resolve these issues but also increase patient safety.
BioInteractions has developed Astute to improve device surface hemocompatibility by mimicking the endothelial layer. The coating has obtained clinical recognition for its safe and successful use on Class III blood contacting medical devices for more than 30 years. The multi-action technology confronts clot formation on devices to provide biocompatibility and antithrombogenicity over long periods of time. Astute contains an active component that interrupts the blood cascade mechanism, preventing platelets from activating and hinders thrombus formation. This ensures the blood remains inactive and does not clot further along in the patient. The coating combines this with passive non-thrombogenic elements to prevent deposition and adhesion on the device surface, enhancing the overall antithrombogenic efficacy. Astute uses only non-leaching components, which reduces patient risk and helps the coating to continue performing without reduction in performance over time.
“We understand the significant risks of both device rejection and increasing HAIs to patient safety, which is why we have worked very hard to develop our non-leaching, antithrombogenic coating solution Astute®,” BioInteractions Commercial Director Arjun Luthra explained. “Thanks to advances in terms of Astute’s platelet adhesion (prevents 95% of platelet formation) and platelet activation (halts blood cascade mechanism by 92%), we have achieved results of more than 98% reduction in blood clot formation. What this all means is that we have a coating solution that when implemented on an indwelling device, turns it into a permanent implant that has improved performance, therefore enhancing life with an implant, whilst reducing the need for further surgeries and ultimately, improving patient safety.”
BioInteractions has more than 30 years experience in R&D, specializing in biocompatible material technologies for the global medical device industry. Based in purpose-built laboratories in the Thames Valley Science Park at the University of Reading (United Kingdom), the company develops advanced and specialized coatings for devices used in medical treatments and procedures ranging from Class I to Class III implants. The company has been a critical supplier to the medical device industry; its portfolio of multi-action materials confronts chronic challenges such as thrombus formation, infections, complications at the tissue-device interface, and various other biocompatible challenges faced by partners. BioInteractions has secured licensing contracts with major medical device manufacturers worldwide and, in 2002, won the Queen’s Award for Enterprise for a biocompatible coating that was the first to combine multiple elements for enhanced long-term antithrombogenic activity for all materials and shapes in just one coating.
BioInteractions is exhibiting at Compamed, Hall 8B, stand number N20. Compamed runs through Nov. 16 in Düsseldorf, Germany.
